|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.40 USD | -0.57% |
|
-8.45% | -38.90% |
| 06:27am | Kennedy's new US vaccine panel to discuss measles shot for children | RE |
| 06:27am | Kennedy's new US vaccine panel to discuss measles shot for children | RE |
| Capitalization | 9.82B 8.53B 8.03B 7.29B 13.44B 849B 15.06B 94.23B 36.42B 388B 36.86B 36.08B 1,420B | P/E ratio 2025 * |
-2.51x | P/E ratio 2026 * | -3.43x |
|---|---|---|---|---|---|
| Enterprise value | 4.43B 3.85B 3.62B 3.29B 6.07B 383B 6.8B 42.54B 16.44B 175B 16.64B 16.29B 641B | EV / Sales 2025 * |
2.14x | EV / Sales 2026 * | 2.9x |
| Free-Float |
90.48% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | -0.57% | ||
| 1 week | -8.45% | ||
| Current month | -4.35% | ||
| 1 month | +2.19% | ||
| 3 months | -24.86% | ||
| 6 months | -33.77% | ||
| Current year | -38.90% |
| 1 week | 25.06 |  | 27.35 |
| 1 month | 25.06 | | 30.3 |
| Current year | 23.15 | | 48.92 |
| 1 year | 23.15 | | 138.07 |
| 3 years | 23.15 | | 217.25 |
| 5 years | 23.15 | | 497.49 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 52 | 01/03/2011 |
James Mock
DFI | Director of Finance/CFO | 48 | 06/09/2022 |
Stephen Hoge
PSD | President | 49 | 01/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 66 | 01/06/2018 |
Noubar Afeyan
CHM | Chairman | 61 | 01/02/2012 |
Stéphane Bancel
BRD | Director/Board Member | 52 | 01/03/2011 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.57% | -8.45% | -80.94% | -80.16% | 9.82B | ||
| -0.80% | -4.97% | +17.11% | +13.05% | 48.38B | ||
| -18.96% | +285.80% | +58,645.35% | +5,549.30% | 31.33B | ||
| -0.45% | -3.61% | +63.51% | +91.43% | 32.21B | ||
| +0.33% | -2.66% | -27.36% | -21.50% | 26.75B | ||
| +0.31% | +0.06% | -1.04% | +20.47% | 26.19B | ||
| -0.96% | -0.83% | +14.31% | -16.87% | 12.52B | ||
| -1.48% | -2.41% | +127.74% | - | 11.96B | ||
| +1.11% | -1.45% | -54.99% | -28.60% | 11.41B | ||
| -1.27% | -0.59% | +38.57% | +103.42% | 10.31B | ||
| Average | -2.08% | +36.34% | +5,874.23% | +625.62% | 22.09B | |
| Weighted average by Cap. | -2.91% | +52.15% | +8,329.88% | +847.77% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.07B 1.8B 1.69B 1.54B 2.83B 179B 3.18B 19.87B 7.68B 81.87B 7.77B 7.61B 299B | 2.4B 2.08B 1.96B 1.78B 3.28B 207B 3.68B 23.01B 8.89B 94.81B 9B 8.81B 347B |
| Net income | -3.9B -3.39B -3.19B -2.9B -5.34B -337B -5.98B -37.44B -14.47B -154B -14.64B -14.33B -564B | -2.88B -2.5B -2.35B -2.14B -3.94B -249B -4.42B -27.62B -10.67B -114B -10.8B -10.57B -416B |
| Net Debt | -5.39B -4.68B -4.4B -4B -7.37B -466B -8.26B -51.69B -19.98B -213B -20.22B -19.79B -779B | -2.88B -2.5B -2.35B -2.14B -3.94B -249B -4.41B -27.59B -10.66B -114B -10.79B -10.57B -416B |
More financial data
* Estimated data
Employees
5,800
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/06/25 | 25.40 $ | -0.59% | 7,526,988 |
| 17/06/25 | 25.55 $ | -1.73% | 8,329,478 |
| 16/06/25 | 26.00 $ | -2.51% | 10,666,074 |
| 13/06/25 | 26.67 $ | -2.49% | 7,180,263 |
| 12/06/25 | 27.35 $ | -1.44% | 8,326,399 |
Delayed Quote Nasdaq, June 19, 2025 at 03:59 am
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
25.40USD
Average target price
47.59USD
Spread / Average Target
+87.37%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition